Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


Nonpsychotropic Synthetic Cannabinoids

Author(s): Emil Pop

Affiliation: Alchem Laboratories Corporation, 13305 Rachael Boulevard, Alachua, FL, USA


Unlike natural cannabinoids which belong to the 6aR - trans series, the synthetic dexanabinol (HU-211), a 6aS-trans enantiomer, does not have affinity toward cannabinoid receptors and is devoid of cannabimimetic activity. On the other hand, dexanabinol demonstrated significant neuroprotective properties which prompted its development as a therapeutic agent. We now present the extension of a series of 6aS-trans cannabinoids with novel derivatives, including water soluble derivatives and congeners of dexanabinol.

Keywords: Nonpsychotropic Synthetic Cannabinoids, 6aR - trans series, synthetic dexanabinol (HU-211), a 6aS-trans enantiomer, cannabimimetic activity, neuroprotective properties, therapeutic agent, 6aS-trans cannabinoids, Delta 9 tetrahydrocannabinol (THC), 6aS-trans enantiomeric series, noncompetitive N-methyl-D-aspartate (NMDA), tumor necrosis factor (TNF alpha), NMDA, Structures of dexanabinol (1) and HU-210 (2), DEXANABINOL, PM3, Glycinate, substituted glycinate esters, Hetrocyclic nitrogen containing esters, Phenolic ester, Phosphate esters, Hemiesters, Pyridine 3 carboxylates, NMDA Receptor Binding, 6aS trans cannabinoids, Lactate dehydrogenase (LDH), NMDA Receptor binding properties, Novel 6aS trans cannabinoids, Gas or liquid chromatographic mass spectrometry (GC MS or LC-MS)

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1347 - 1359]
Pages: 13
DOI: 10.2174/1381612003399446
Price: $58